REGENERON PHARMACEUTICALS, INC.
REGNAPI behind this page
REGN Q3 2025 request
Playground key active
/api/financials?ticker=REGN&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 3,754.3 | 3,720.7 | +0.9% |
Show Product Lines breakouts |
|||
| Collaboration revenue | 1,968.4 | 1,660.1 | +18.6% |
| ELYEA HD And EYLEA · US | 1,111.2 | 1,536.9 | -27.7% |
| ELYEA HD · US | 430.6 | 392.3 | +9.8% |
| Evkeeza · US | 42.8 | 32.4 | +32.1% |
| EYLEA · US | 680.6 | 1,144.6 | -40.5% |
| Libtayo | 365.2 | 288.6 | +26.5% |
| Libtayo · Non Us | 146.1 | 94.1 | +55.3% |
| Libtayo · US | 219.1 | 194.5 | +12.6% |
| Other products | 0.8 | — | — |
| Praluent · US | 67.7 | 52.9 | +28.0% |
| Product | 1,587.7 | 1,946.4 | -18.4% |
| Product And Service Other | 198.2 | 114.2 | +73.6% |
| Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses · Non Us | -3.9 | -11.8 | +66.9% |
| Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses · Sanofi Collaboration Agreement, Antibody | -23.5 | -7.8 | -201.3% |
| Regeneron's share of profits · Non Us | 311.9 | 367.6 | -15.2% |
| Regeneron's share of profits · Sanofi Collaboration Agreement, Antibody | 1,455.5 | 1,088.3 | +33.7% |
| Reimbursement for manufacturing of commercial supplies · Non Us | 32.9 | 23.2 | +41.8% |
| Reimbursement for manufacturing of commercial supplies · Sanofi Collaboration Agreement, Antibody | 161.5 | 175.1 | -7.8% |
| Reimbursement of commercialization-related expenses · Sanofi Collaboration Agreement, Antibody | 182.6 | 169 | +8.0% |
| Research & Development | 1,475 | 1,271.5 | +16.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,475 | 1,271.5 | +16.0% |
| Reportable Segment · Clinical manufacturing costs | 381.4 | 306.6 | +24.4% |
| Reportable Segment · Direct research and development expenses | 454.3 | 386.4 | +17.6% |
| Reportable Segment · Indirect research and development expenses: | 67.5 | 63 | +7.1% |
| Reportable Segment · Indirect research and development expenses: | 166.3 | 158.7 | +4.8% |
| Reportable Segment · Indirect research and development expenses: | 438.3 | 407.8 | +7.5% |
| Reportable Segment · Indirect research and development expenses: | 672.1 | 629.5 | +6.8% |
| Acquired In Process Research And Development | 83.1 | 56.2 | +47.9% |
| Selling, General & Administrative | 657.8 | 714.4 | -7.9% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Cost of collaboration and contract manufacturing | 240.6 | 228.8 | +5.2% |
| Product | 281 | 262.3 | +7.1% |
| Other Operating Income Expense Net | -10 | 8 | -225.0% |
| Total Costs & Expenses | 2,727.5 | 2,541.2 | +7.3% |
| Operating Income | 1,026.8 | 1,179.5 | -12.9% |
| Other Non-Operating Income (Expense) | 755.8 | 327.3 | +130.9% |
| Interest Expense | -19.3 | -13.8 | -39.9% |
| Non-Operating Income (Expense) | 736.5 | 313.5 | +134.9% |
| Income Before Taxes | 1,763.3 | 1,493 | +18.1% |
| Income Tax Expense (Benefit) | 303.3 | 152.4 | +99.0% |
| Net Income | 1,460 | 1,340.6 | +8.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,460 | 1,340.6 | +8.9% |
| EPS (Basic) | 14.09 | 12.4 | +13.6% |
| EPS (Diluted) | 13.62 | 11.54 | +18.0% |
| Wtd Avg Shares (Basic) | 103.6 | 108.1 | -4.2% |
| Wtd Avg Shares (Diluted) | 107.2 | 116.2 | -7.7% |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 15.7 | 128.2 | -87.8% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 0.8 | 1.9 | -57.9% |
| Comprehensive Income | 1,476.5 | 1,470.7 | +0.4% |
| Other Comprehensive Income | 16.5 | 130.1 | -87.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 16.5 | 130.1 | -87.3% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,506.4 | 2,011.8 | +24.6% |
| Marketable Securities (Current) | 5,937.2 | 7,784.7 | -23.7% |
| Accounts Receivable | 5,687.1 | 6,107.1 | -6.9% |
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts |
|||
| Trade Accounts Receivable | 3.47 | 4.14 | -16.2% |
Show Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project breakouts |
|||
| Bayer | 363.2 | 377.2 | -3.7% |
| Sanofi Collaboration Agreement, Antibody | 1,493.9 | 1,270.5 | +17.6% |
| Inventory | 3,254.4 | 3,018 | +7.8% |
| Prepaid Expenses & Other Current Assets | 595.6 | 412 | +44.6% |
| Total Current Assets | 17,980.7 | 19,333.6 | -7.0% |
| Non-Current Assets | |||
| Marketable Securities (Non-Current) | 10,285.7 | 8,490.9 | +21.1% |
| Deferred Tax Assets | 3,846.7 | 3,015.1 | +27.6% |
| Other Non-Current Assets | 1,673.1 | 1,043 | +60.4% |
| Total Assets | 40,169.4 | 37,441.9 | +7.3% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 5,002.3 | 4,439.2 | +12.7% |
| Intangible Assets Net Excluding Goodwill | 1,380.9 | 1,120.1 | +23.3% |
| Current Liabilities | |||
| Accounts Payable | 903.8 | 497.3 | +81.7% |
| Accrued Liabilities And Other Liabilities | 2,975.7 | 2,536.5 | +17.3% |
| Deferred Revenue (Current) | 545.6 | 627.2 | -13.0% |
| Total Current Liabilities | 4,425.1 | 3,661 | +20.9% |
| Non-Current Liabilities | |||
| Long-Term Debt | 1,985.5 | 1,984 | +0.1% |
| Finance Lease Liability Noncurrent | 720 | 720 | 0.0% |
| Contract With Customer Liability Noncurrent | 219.2 | 207.4 | +5.7% |
| Other Non-Current Liabilities | 1,861.8 | 1,543.6 | +20.6% |
| Total Liabilities | 9,211.6 | 8,116 | +13.5% |
| Stockholders' Equity | |||
| Common Stock (Q) | — | — | — |
Show Statement Class Of Stock breakouts |
|||
| Common Stock | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 13,787.3 | 12,702.8 | +8.5% |
| Retained Earnings | 35,045.8 | 30,755.2 | +14.0% |
| Accumulated Other Comprehensive Income | 69 | 60.2 | +14.6% |
| Treasury Stock Common Value | -17,944.4 | -14,192.4 | -26.4% |
| Total Stockholders' Equity | 30,957.8 | 29,325.9 | +5.6% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 69 | 60.2 | +14.6% |
| Additional Paid In Capital | 13,787.3 | 12,702.8 | +8.5% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 35,045.8 | 30,755.2 | +14.0% |
| Treasury Stock Common | -17,944.4 | -14,192.4 | -26.4% |
| Total Liabilities & Equity | 40,169.4 | 37,441.9 | +7.3% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 398.7 | 356.5 | +11.8% |
| Stock-Based Compensation | 744.4 | 678.4 | +9.7% |
| Marketable And Other Securities Gain Loss | -967.6 | -331.2 | -192.1% |
| Other Non-Cash Items | -1.4 | -31.9 | +95.6% |
| Increase Decrease In Deferred Income Taxes | -552.9 | -477.1 | -15.9% |
| Change in Accounts Receivable | 549.3 | -436.2 | +225.9% |
| Change in Inventory | -277.4 | -502 | +44.7% |
| Change in Prepaid & Other Assets | -458.1 | -352.2 | -30.1% |
| Change in Deferred Revenue | -48.6 | 249 | -119.5% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 761.5 | 509.5 | +49.5% |
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | 147.9 | -337.2 | +143.9% |
| Net Cash from Operations | 3,808.2 | 3,157.7 | +20.6% |
| Investing Activities | |||
| Payments To Acquire Marketable Securities | -8,914.6 | -14,664.5 | +39.2% |
| Proceeds From Sale And Maturity Of Marketable Securities | 8,991.2 | 12,445.3 | -27.8% |
| Payments To Acquire Productive Assets | -649.7 | -556.3 | -16.8% |
| Payments To Acquire Intangible Assets1 | -273.3 | -58.3 | -368.8% |
| Payments To Acquire Businesses Net Of Cash Acquired | -3 | -5 | +40.0% |
| Net Cash from Investing | -849.4 | -2,818.7 | +69.9% |
| Financing Activities | |||
| Proceeds From Issuance Of Common Stock | 132.4 | 1,374.4 | -90.4% |
| Tax Withholding for Share Compensation | -12.9 | -775.7 | +98.3% |
| Share Repurchases | -2,766.9 | -1,630.3 | -69.7% |
| Payments Of Dividends | -277.6 | — | — |
| Proceeds From Payments For Other Financing Activities | -10.3 | -33.4 | +69.2% |
| Net Cash from Financing | -2,935.3 | -1,065 | -175.6% |
| Supplemental | |||
| Unpaid Capital Expenditures | 176.9 | 94 | +88.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 0.6 | — | — |
| Net Change in Cash | 24.1 | -726 | +103.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,513.1 | 2,011.8 | +24.9% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.